Northern Trust’s Benitec Biopharma BNTC Stock Holding History

Northern Trust’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.68M	Buy	157,324 +31,164	+25%	+$361K	﹤0.01%	3068
2025 Q4	$1.7M	Sell	126,160 -4,455	-3%	-$61.6K	﹤0.01%	3094
2025 Q3	$1.83M	Buy	130,615 +4,293	+3%	+$54.8K	﹤0.01%	3084
2025 Q2	$1.48M	Buy	126,322 +80,445	+175%	+$1.13M	﹤0.01%	3172
2025 Q1	$597K	Buy	45,877 +7,677	+20%	+$92.9K	﹤0.01%	3499
2024 Q4	$482K	Buy	38,200 +13,425	+54%	+$145K	﹤0.01%	3667
2024 Q3	$228K	Sell	24,775 -149	-0.6%	-$1.33K	﹤0.01%	3840
2024 Q2	$174K	Buy	+24,924	New	+$184K	﹤0.01%	3901
2023 Q3	–	Sell	-695	Closed	-$2.82K	–	4474
2023 Q2	$2.82K	Hold	695	–	–	﹤0.01%	4525
2023 Q1	$2.48K	Hold	695	–	–	﹤0.01%	4574
2022 Q4	$2.01K	Hold	695	–	–	﹤0.01%	4641
2022 Q3	$4K	Hold	695	–	–	﹤0.01%	4681
2022 Q2	$14K	Hold	695	–	–	﹤0.01%	4663
2022 Q1	$28K	Hold	695	–	–	﹤0.01%	4634
2021 Q4	$31K	Hold	695	–	–	﹤0.01%	4663
2021 Q3	$42K	Hold	695	–	–	﹤0.01%	4558
2021 Q2	$50K	Buy	+695	New	+$54.4K	﹤0.01%	4498

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Northern Trust's BNTC Position: Q1 2026 in Review

Northern Trust increased its Benitec Biopharma (BNTC) stake by 25% in Q1 2026, buying an estimated $361K and bringing the position to 157,324 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3068.

Northern Trust first reported a position in BNTC in Q2 2021 and has held it in 17 quarters since. The position peaked at $1.83M in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Northern Trust held 157,324 shares of Benitec Biopharma worth $1.68M as of Q1 2026.
Northern Trust bought 31,164 Benitec Biopharma shares in Q1 2026, an estimated $361K.
Benitec Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3068 holding.
Northern Trust first reported a position in Benitec Biopharma in Q2 2021 and has held it in 17 quarters since.
Northern Trust's Benitec Biopharma position peaked at $1.83M in Q3 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.